We had a dual aim: (1) to identify risk factors for RCC development, and in particular to investigate the impact of IBD therapy on RCC development (2) to compare RCC characteristics, outcome and survival between IBD patients and the general population, including the impact of immunosuppression and anti-TNFα agents. Here, TNF is linked to inflammatory bowel disease.